Original Research
Published on 24 Oct 2023
Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1268117
- 6,369 views
- 7 citations




